Improving hepatitis C treatment in drug treatment clinics

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The ETHOS ENGAGE project aims to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs across New South Wales, Australia. This non-randomised trial will assess the impact of on-site HCV RNA testing, liver fibrosis assessment, and linkage to care to improve access to direct-acting antiviral therapy for individuals with a history of injecting drug use. Participants will also complete a survey and may consent to link their data with existing population databases for comprehensive analysis. The project is part of a larger initiative to develop a framework for HCV screening and treatment in similar settings nationwide.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant has voluntarily signed the informed consent form;
* 18 years of age or older;
* History of injecting drug use\*;
* Recent injecting drug use (previous six months) or currently receiving OST\*.

  * These criteria will not apply for recruitment from residential rehabilitation centres

Exclusion Criteria:

* Nil

Where it's running

• Canberra Alliance for Harm Minimisation & Advocacy (CAHMA)
  Canberra, Australian Capital Territory, Australia Recruiting
• Blacktown Methadone Management Clinic
  Blacktown, New South Wales, Australia Recruiting
• NSLHD Brookvale Community Health Centre
  Brookvale, New South Wales, Australia Recruiting
• Campbelltown Drug Health Services
  Campbelltown, New South Wales, Australia Recruiting
• MNCLHD Coffs Harbour Alcohol and Other Drug Services
  Coffs Harbour, New South Wales, Australia Recruiting
• Rankin Court Treatment Centre
  Darlinghurst, New South Wales, Australia Recruiting

Study contacts

• Study coordinator: David Silk, BSc
• Email: dsilk@kirby.unsw.edu.au
• Phone: +61 2 9385 0878

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Glecaprevir/pibrentasvir started during pregnancy for women with hepatitis C, with or without HIV

  This trial will test whether taking glecaprevir/pibrentasvir during pregnancy is safe and how the drug is processed in pregnant women who have hepatitis C, including those who also have HIV, and will follow their infants for 10 weeks after birth.

  Recruiting at 8 sites Phase 1/2 National Institute of Allergy and Infectious Diseases (NIAID) · Los Angeles, California and 9 other locations · NCT07040319

• Evaluating hepatitis C treatment during pregnancy

  This study tests how well a new hepatitis C treatment works for pregnant adults with a history of drug use and looks at their experience during the treatment.

  Recruiting at 2 sites Washington University School of Medicine · St Louis, Missouri and 1 other locations · NCT06367465

• Decentralized treatment for hepatitis C in Brazil

  This study is testing a new way to treat hepatitis C in Brazil using a medication called Epclusa to see if it helps more people get the care they need compared to traditional methods.

  Recruiting at 2 sites Phase 4 Oswaldo Cruz Foundation · Rio de Janeiro, Rio de Janeiro and 1 other locations · NCT06306300

• Helping young people who inject drugs start treatment for Hepatitis C

  This study tests a new support program to help young adults who inject drugs start treatment for Hepatitis C and see if it works better than regular care.

  Recruiting University of California, San Francisco · San Francisco, California · NCT06179498

• Simplified hepatitis C testing with same-day treatment for people who inject drugs in Armenia, Georgia and Tanzania

  This project will test whether a simplified pathway that starts hepatitis C treatment the same day after a quick antibody test helps people who inject drugs in Armenia, Georgia, and Tanzania get treated and cured faster than the usual antibody-plus-RNA pathway.

  Recruiting Early Phase 1 Médecins du Monde · Yerevan · NCT06159504

• Point-of-care testing program for Hepatitis C screening

  This study is testing if quick Hepatitis C tests done during a single visit can help more at-risk adults get diagnosed and start treatment faster.

  Recruiting at 6 sites Kirby Institute · Canberra, Australian Capital Territory and 12 other locations · NCT05713136

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.